Market Intelligence, Clinical Progress, and High-Purity Reagents for Autoimmune and Immuno-Oncology Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for TNFSF8/CD153 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | TNFSF8/CD153 ECD-Fc Fusion Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 expressed (native glycosylation) for proper trimeric folding and disulfide bridging. |
View TNFSF8 Products |
| Gene Delivery | TNFSF8/CD153 Premade ORF Lentivirus Full-length ORF for stable cell line generation preserving native Type II membrane topology. |
View TNFSF8 Products |
| Benchmark Ab | Anti-TNFSF8/CD153 Neutralizing Antibody (Research Grade) Recombinant positive control for blocking assays, binding competition, and assay standardization. |
View TNFSF8 Products |
| Validator | TNFSF8/CD153 siRNA Set Sequence-verified for knockdown specificity controls and baseline checks. |
View TNFSF8 Products |
| Related Target: CD30 | TNFRSF8 (CD30) Canonical receptor; essential for binding, blockade, and selectivity assays. |
View TNFRSF8 Products |
| Related Target: OX40L | TNFSF4 (OX40L) Structural homolog within TNF superfamily; critical for off-target counter-screening. |
View TNFSF4 Products |
| Related Target: CD40L | CD40LG/TNFSF5 Synergistic costimulation pathway member; useful for combination studies and cross-reactivity panels. |
View CD40LG Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Native trimeric conformation required for TNF ligand function | ECD-Fc engineered to support oligomeric assembly; HEK293 expressed for native folding, glycosylation, and verified disulfide bridging. Theoretical MW confirmed by mass spec. |
| Cross-species cyno/mouse/human pharmacology | Human, Mouse, and Cynomolgus TNFSF8 ortholog proteins available with >95% purity and sequence verification. |
| TNF superfamily off-target liability | Homolog panel (TNFSF4, TNF, CD40LG, etc.) strictly sequence-verified by mass spec for selectivity screening. |
| Blocking antibody validation | Matched TNFRSF8 (CD30) recombinant protein included for competition assays and binding pair validation. |
| Cell-based functional assays | Lentivirus particles for stable TNFSF8-expressing lines; native conformation preserved for co-culture and reporter assays. |
| Specificity verification | Sequence-verified siRNA included for knockdown specificity checks and baseline noise reduction. |
Live TNFSF8/CD153 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The TNFSF8/CD153 (CD30L) axis represents an emerging frontier in immune modulation. While receptor-targeted modalities against CD30 (e.g., Brentuximab vedotin) have achieved clinical validation in hematological malignancies, direct ligand-focused strategies remain in preclinical optimization. The field is shifting from oncology adjuvants toward autoimmune modulation, with first-generation antagonist antibodies entering preclinical development for rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), and graft-versus-host disease (GvHD). Major players (including Sanofi, Novartis) and academic consortia are exploring TNFSF8 as a target for severe autoimmune conditions and as an immunomodulatory checkpoint. As the field advances, differentiation will depend on precise TNF superfamily selectivity, robust cross-species pharmacology, and reagents that preserve the native trimeric architecture of this Type II membrane ligand.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Monoclonal Antibody (Antagonist) | Academic Consortia, Autoimmune-Focused Biotech (Sanofi, Novartis class-wide) | Rheumatoid Arthritis, SLE, GvHD | Receptor Blocking Assay (Need high-purity trimeric ECD-Fc + CD30 pair) |
| Bispecific Antibody | Immuno-oncology Startups, Emerging Biotechs | Solid tumors, Lymphoma, Refractory Autoimmunity | Heterodimer Validation & cross-reactive ortholog panels |
| Soluble Receptor-Fc / Traps | Research Institutes, Academic/Early Stage | GVHD, Inflammatory diseases | Binding kinetics/affinity (Need trimeric TNFSF8 antigen with verified theoretical MW) |
| CAR-T Validation Tools | Cell Therapy Companies | Relapsed Lymphoma | Target expression controls (Need TNFSF8 Lentivirus for stable cell lines) |